This is the first investigation with clear evidence that the OLE, as a potential insulin stimulator, can be used for the treatment of diabetes via the improvement of intracellular GLUT4 translocation in the skeletal muscle by the activation of Rab8A and Rab13 proteins. This evidence concerns the gene RAB8A and diabetes mellitus.